Townsquare Capital LLC Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Townsquare Capital LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 41.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,345 shares of the biopharmaceutical company’s stock after selling 966 shares during the period. Townsquare Capital LLC’s holdings in Regeneron Pharmaceuticals were worth $756,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of REGN. SYM FINANCIAL Corp acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $249,000. Summit Global Investments purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth $11,034,000. Ruffer LLP acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $12,111,000. AE Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals by 52.1% in the third quarter. AE Wealth Management LLC now owns 4,004 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 1,371 shares in the last quarter. Finally, Tidemark LLC increased its position in shares of Regeneron Pharmaceuticals by 12.3% in the third quarter. Tidemark LLC now owns 522 shares of the biopharmaceutical company’s stock valued at $294,000 after buying an additional 57 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. HSBC initiated coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 price target on the stock. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a research note on Friday, December 12th. Finally, Citigroup raised their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $784.77.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $741.45 on Friday. The company has a market cap of $77.93 billion, a P/E ratio of 17.76, a P/E/G ratio of 1.95 and a beta of 0.39. The business has a fifty day simple moving average of $758.39 and a 200-day simple moving average of $649.85. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the company earned $12.07 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Company beat Q4 revenue and EPS estimates (qtrly revenue $3.88B; EPS $11.44 vs. consensus ~$10.74), helped by Dupixent and Eylea HD sales — a near-term fundamental driver supporting the stock. GlobeNewswire – Q4 Results
• Positive Sentiment: Board raised the quarterly dividend to $0.94 (a ~6.8% increase vs. prior $0.88), signaling confidence in cash flow and making the stock slightly more attractive to income-focused investors.
• Positive Sentiment: Analyst optimism persists — Raymond James reiterated a Buy and set an $870 target; Evercore/ISI and others have also lifted targets, which can support demand on dips. TipRanks – Raymond James
• Positive Sentiment: Pipeline update: management highlighted an experimental obesity drug with added cholesterol-lowering benefits that could differentiate it in a crowded market — a potential medium-term growth driver. Reuters – Obesity drug story
• Neutral Sentiment: Full earnings materials and the Q4 earnings call transcript are available for deeper detail — useful for investors who want guidance commentary and pipeline timing. Seeking Alpha – Call Transcript
• Negative Sentiment: Despite the beats, EPS declined year-over-year (from $12.07 to $11.44) as higher expenses weighed on profitability — a headline that likely pressured sentiment. Reuters – Profit beat but EPS down YoY
• Negative Sentiment: Core Eylea weakness and investor concerns about sustainability of growth prompted some sell-side caution and profit-taking even after the beat, which helps explain the share decline today. MSN – Why shares fell

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.